Angiogenesis in salivary carcinomas with and without myoepithelial differentiation.
To investigate whether salivary carcinomas with and without myoepithelial differentiation could present differences regarding degree of angiogenesis, we compared tumor vascularization between adenoid cystic (31 cases) and epithelial-myoepithelial carcinomas (14) versus mucoepidermoid (37) carcinoma. The expression of peroxiredoxin I was also studied to verify the potential relationship between cellular metabolism and microvascular density. Microvascular density for CD34 and CD105 were significantly lower in carcinomas with myoepithelial differentiation. However, no correlation was found between degree of angiogenesis and amounts of myoepithelial cells. High-grade peroxiredoxin I expression was found in 73.7% of mucoepidermoid carcinomas, whereas 85.1% of carcinomas with myoepithelial differentiation presented low-grade expression. In conclusion, carcinomas with myoepithelial differentiation, regardless of the amounts of myoepithelial cells, are associated to a significantly lower vascular density. The reasons for this lower angiogenic activity remain to be determined but could be related to metabolic characteristics of the cancer cells.
Costa
A F
AF
Department of Pathology, Faculty of Medical Sciences, University of Campinas, Campinas, Sao Paulo, Brazil.
Demasi
A P D
AP
Bonfitto
V L L
VL
Bonfitto
J F L
JF
Furuse
C
C
Araújo
V C
VC
Metze
K
K
Altemani
A
A
D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism; D018952:Antigens, CD34 / Q000378:metabolism; D003528:Carcinoma, Adenoid Cystic / Q000473:pathology; D018277:Carcinoma, Mucoepidermoid / Q000473:pathology; D002454:Cell Differentiation; D000071063:Endoglin; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009208:Myoepithelioma / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000473:pathology*; D011956:Receptors, Cell Surface / Q000378:metabolism; D012468:Salivary Gland Neoplasms / Q000378:metabolism / Q000473:pathology*
D015703:Antigens, CD; D018952:Antigens, CD34; C064206:ENG protein, human; D000071063:Endoglin; D011956:Receptors, Cell Surface
J Surg Oncol. 2006 May 1;93(6):446-55
16615157
FASEB J. 2003 Jun;17(9):984-92
12773481
Br J Cancer. 2000 Feb;82(4):844-51
10732757
Cancer Metastasis Rev. 1990 Nov;9(3):171-4
1705485
Nat Biotechnol. 1997 Aug;15(8):778-83
9255794
J Pathol. 1996 Apr;178(4):363-6
8691311
Cancer Res. 1994 Jul 1;54(13):3333-6
8012945
Virchows Arch. 2007 Jul;451(1):65-71
17593387
APMIS. 2004 Jul-Aug;112(7-8):413-30
15563306
J Clin Pathol. 1998 Jul;51(7):506-11
9797726
BMC Cancer. 2007 Jun 01;7:95
17543095
Anticancer Res. 2001 Nov-Dec;21(6B):4311-6
11908685
Microsc Res Tech. 2001 Feb 15;52(4):437-49
11170303
Science. 2003 Apr 25;300(5619):650-3
12714747
Semin Cancer Biol. 2003 Apr;13(2):159-67
12654259
J Cell Sci. 2003 Jul 1;116(Pt 13):2677-85
12746487
J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):249-60
16807804
Nature. 2000 Nov 9;408(6809):239-47
11089981
Prog Histochem Cytochem. 2003;38(4):343-426
14509196
Hum Pathol. 2006 Jul;37(7):861-6
16784986
J Clin Oncol. 1995 Mar;13(3):765-82
7533829
BMC Cancer. 2006 May 02;6:110
16650286
J Natl Cancer Inst. 2002 Jun 19;94(12):883-93
12072542
World J Gastroenterol. 2003 Jun;9(6):1144-55
12800214
Int J Cancer. 1993 May 28;54(3):363-70
8509210
Oncogene. 2000 Jul 20;19(31):3449-59
10918603
J Cell Physiol. 2001 Jul;188(1):1-7
11382917
J Biol Chem. 1999 Jan 8;274(2):584-94
9872992
Anticancer Res. 1998 Sep-Oct;18(5A):3621-8
9858949
Int J Surg Pathol. 2005 Jan;13(1):57-65
15735856